The analyses show that patients with HD have a higher percentage of mDC BDCA-1CD19− (by 88.88%) and pDC BDCA-2+CD123+ (by 113.04%), as well as a decrease in the percentage of classical MONs CD14+CD16− (by 7.84%) in PB compared to patients in the control group (Table 2). This evidence concerns the gene CD14 and Huntington disease.